Medical Description: Nilotinib Capsules 150 mg & 200 mg

Prescription medicine | Antineoplastic agent | Tyrosine kinase inhibitor

Active ingredient: Nilotinib

Available strengths:

• Nilotinib 150 mg capsules.
• Nilotinib 200 mg capsules.

Product Overview

Nilotinib is an oral targeted anticancer medicine belonging to the tyrosine kinase inhibitor (TKI) class. It is used to treat specific forms of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), a cancer of the blood-forming cells characterized by the abnormal BCR::ABL1 protein.

Nilotinib works by inhibiting the abnormal BCR::ABL1 tyrosine kinase, which helps block signals responsible for the uncontrolled growth and multiplication of leukemia cells. This targeted action helps control disease progression.

Indications and Uses

Nilotinib capsules are indicated, according to the applicable product labeling, for:

• Newly diagnosed Ph+ CML in the chronic phase in eligible patients.
• Ph+ CML in the chronic or accelerated phase in adults whose disease is resistant to or who cannot tolerate previous treatment that included imatinib.
• Certain pediatric patients with Ph+ CML, depending on age, disease phase, previous treatment, and the specific approved product labeling.

Nilotinib is a targeted treatment for specific types of leukemia; it is not intended for general use against other cancers without a specialist's recommendation.

Mechanism of Action

Nilotinib selectively inhibits the BCR::ABL1 tyrosine kinase, an abnormal enzyme produced by the Philadelphia chromosome translocation. This enzyme continuously activates signals that promote leukemia-cell growth and survival.

By binding to the kinase domain and inhibiting its activity, nilotinib suppresses BCR::ABL1-mediated cell proliferation and helps reduce the number of leukemia cells.

Dosage and Administration

• Nilotinib is generally administered orally twice daily, with doses determined by the patient's diagnosis, treatment history, response, and tolerability.
• The exact prescribed regimen may differ between newly diagnosed disease and disease resistant to or intolerant of previous treatment.
• Fasting is essential for nilotinib capsules: take at least 2 hours after the last meal and wait at least 1 hour after each dose before eating.
• Take the medication at consistent times and follow the treating hematologist's instructions.
• Do not change the dose, discontinue treatment, or substitute one formulation for another without medical advice.

Important: The 150 mg and 200 mg capsule strengths are not, by themselves, the recommended dose. The appropriate number of capsules per dose must be prescribed by the specialist.

Contraindications and Warnings

Nilotinib has a boxed warning for QT-interval prolongation and sudden deaths. It requires careful assessment and monitoring.

• Cardiac risk: May cause QT prolongation and potentially life-threatening abnormal heart rhythms. It is contraindicated in patients with long QT syndrome, hypokalemia, or hypomagnesemia under the cited prescribing information.
• Blood disorders: May cause low levels of blood cells, increasing the risk of infection, anemia, and bleeding.
• Cardiovascular complications: May increase the risk of arterial vascular occlusive events, including serious cardiovascular complications.
• Liver toxicity: Liver function requires monitoring.
• Pancreatic effects: May increase pancreatic enzyme levels and, in some cases, cause pancreatitis.
• Drug interactions: Certain medicines, including strong CYP3A4 inhibitors and drugs that prolong the QT interval, may increase the risk of serious adverse effects.
• Pregnancy and breastfeeding: May harm an unborn baby. Pregnancy prevention and breastfeeding precautions should be discussed with the treating specialist.

Possible Side Effects

Common or reported adverse effects include:

• Nausea, vomiting, diarrhea, or constipation.
• Headache, fatigue, and dizziness.
• Skin rash or itching.
• Muscle cramps and joint, bone, or muscle pain.
• Changes in blood cell counts.
• Elevated liver enzymes or pancreatic enzymes.

Seek urgent medical attention for fainting, seizures, a rapid or irregular heartbeat, chest pain, sudden weakness or difficulty speaking, unusual bleeding, or severe abdominal pain.

Drug and Food Interactions

• Avoid grapefruit, grapefruit juice, and grapefruit-containing supplements.
• Inform the treating physician about all prescription medicines, over-the-counter products, vitamins, and herbal supplements.
• Antacids containing aluminum or magnesium and certain medicines used for acid reflux may require specific timing adjustments.
• Do not start or stop interacting medicines without consulting the treating physician or pharmacist.

Storage

Store in the original, tightly closed container at the temperature specified on the product label. Protect from excess heat and moisture, and keep out of the reach of children. Follow the product-specific storage instructions supplied by the manufacturer.

References

The following non-commercial government resources support this description:

1. U.S. National Cancer Institute (NCI) — Nilotinib drug information and mechanism of action: cancer.gov — Nilotinib
2. U.S. National Library of Medicine, MedlinePlus — Indications, administration, precautions, interactions, and side effects: medlineplus.gov — Nilotinib
3. U.S. National Library of Medicine, DailyMed — Official prescribing information, contraindications, dosage forms, and warnings: dailymed.nlm.nih.gov — Nilotinib capsules
4. U.S. Food and Drug Administration (FDA) — Nilotinib capsule prescribing information: FDA — Nilotinib capsules label

Patient Disclaimer

This information is intended for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Nilotinib is a prescription anticancer medicine that must be used under the supervision of a qualified hematologist or oncologist. Patients should not start, stop, or change their treatment without consulting their treating physician. Always read the approved product leaflet and seek immediate medical attention if serious adverse effects occur.